ReviewBMC nephrology2026
Recent advances in the clinical significance and physiological functions of uromodulin: a narrative review.
Review in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uromodulin, also called Tamm-Horsfall protein, is a kidney-specific glycoprotein primarily synthesized in the thick ascending limb of Henle’s loop. This review summarizes recent advances in its multifaceted physiological roles across urinary, interstitial, and circulatory compartments. In urine, It inhibits urinary tract infections and prevents renal stones by modulating calcium/magnesium reabsorption via ion channels. In the interstitium, preclinically and observationally, uromodulin regulates water-salt balance via the sodium-potassium-2-chloride cotransporter 2/sodium-chloride cotransporter (NKCC2/NCC) phosphorylation, influences blood pressure, and exerts dual immunomodulatory effects. Serum uromodulin (sUMOD) exhibits systemic antioxidant activity (preclinical models) and mitigates vascular calcification (in vitro/animal studies), with associations to multiple disease outcomes—suggesting biomarker potential. Despite progress, unresolved questions remain regarding uromodulin’s secretory regulation, post-translational modifications, and therapeutic potential. Key future research priorities are standardizing its detection methods (addressing assay heterogeneity) and clarifying its role in chronic kidney disease (CKD), acute kidney injury (AKI), and cardiovascular diseases. This review comprehensively synthesizes literature to clarify these aspects, emphasizing its physiological roles and observational clinical associations to guide potential clinical translation.Clinical trial number Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.